They had £18m odd at 30/6/24. They burn about £8m a half. So down to about £8m now. So certainly they are preparing to raise as they need to have the next 12 months signed off for going concerned at 31/12/24 accounts.
Go back and look at May 24. A series of very encouraging RNSs spiked the share price to 24p resulting in the June 24 placing and then a slump. I fully expect an exact repeat in Feb 25. |
Nigel,
Correct - they will need to demonstrate they have cash and sufficient of it for twelve months to avoid a going concern clause - but, there is a reasonable possibility that prior to the summer they will increase revenues to such an extent that they can satisfy that this will be the case. |
They'll need cash in the next few months I'd say (unless commercial traction really takes off) to ensure going concern is satisfied but probably no immediate need. |
PATT said the same about Apta two months ago - claiming he knew a placing was being forward sold. Result: no placing and the shares doubled. |
Then filter me. Weird that it was you who decided to post about me on here. That’s why I posted aswell. After you came onto STX to push AGL.
Of course there is a placing coming. Nailed on. |
PATT
Usually I just filter those who repeat themselves
For some reason you feel the need to keep coming back to tell us a placing is coming even though you sold out long ago
Many of us know the history here
At some point a poor performing stock can become viable again
Angle has performed very well since falling to 7.5p
Sometimes you have to be able to change your mind when the situation changes
And the situation here has improved greatly
As you say we are riding a wave but the wave could soon become tidal
sent from my iPhone |
Strong day for agl with very good volume.
Defo background buying imo.
That 200k delayed trade after the bell just another example.
Sentiment beginning to shift here. Any news on renewed contract and this'll pop! |
Strange krypton. I sold out of AGL in tranches at 125p, 98p and 77p having started buying at 30p.
Bad move it seems.
Krypton. You seem to want me to post here. Happy to oblige. If you have watched AN and his history you might be very very wary of reading anything material into the recent RNSs. He skimmed loads of people buying at 80p by issuing such enthusiastic forecasts. None of which have turned into anything. But who knows. Maybe this time it is more than a single webcast of some interesting research. |
Update for PATT
Angle = +12%
Shield Therapeutics = flat/nada/nothing
You still chose the wrong investment
sent from my iPhone |
And here it is !
False alarm rehash of the previous. |
Interview out |
£21 !!!! I’d be over the moon and back with the £10 Newland said was minimum about 3-4 years ago. 😂 right now ( short term) I’d actually settle for £4 😂 so I can enjoy the rest of my passing years in abject luxury ! |
It's been talked about for years. Even with fda ! The contracts so far minuscule . In the meantime another rights to keep it going . |
Yes and breakout on the yr chart. 23p next target price. |
pretty good volume considering no further news released. Perhaps taken a while to sink in. |
I think with Illumina now involved the question is when rather than if...and we know that if an Auction kicks off for AGL it's going to be a $1bn+ takeout |
Well let's hope some one buys angle before the next rights issue ! |
Morning Anglers!
The big volume spike day on release of the Illumina rns now perhaps caters for quite a bit of profit taking from peeps that bought in sub 10p. And why not.
I thought we'd see a decent tree shake but they've not really managed that yet. A gradual climb is perhaps more sustainable but with the microcaps it often doesn't follow that pattern especially if the stocks free~float is rather modest.
edit: ergo looks like perhaps some juicy buy orders being worked....
squeeze on? |
Of interest perhaps, Grail, spun out of Illumina, currently valued just above one billion dollars. Their multi cancer blood test based on DNA analysis is an early detection screener and not a diagnostic test.
The fact the stock has been soaring has to be a positive for Angle and it highlights potential future valuations! |
WashingmachineI would accept a lowball bid at £21 :-) |
 In my opinion - this could be shaping up to be a very "BRITISH STORY"Evidence of ... an inescapable conclusion?-In the latest RNS - I notice a beautiful little sentence that reads:"... ANGLE's Parsortix system offers the potential to undertake "MULTIOMICS" by enabling RNA and "PROTEIN" sequencing on ILLUMINA platforms which is "NOT POSSIBLE" with ctDNA... " https://www.londonstockexchange.com/news-article/AGL/analysis-of-ctc-dna-and-ctdna-using-illumina-assay/16873903-Why "PROTEINS" matter - Proteins are the functional molecules of biology. While DNA and RNA provide the blueprint, PROTEINS DICTATE real-time disease processes, treatment response, and "METASTASIS".-Recently 13JAN25:ILLUMINA launches pilot "PROTEOMICS" program with UK BIOBANK and biopharma collaborators to analyse 50,000 samples. https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=e246b707-1b47-4d28-8ea7-51d380977d3bThe 'buzz' word going forward I feel to be "PROTEOMICS" - as it enables the observation of direct cellular function to improve understanding of the role of "PROTEINS" in health and disease, and facilitates biomarker discovery for conditions such as CANCER.-UK BIOBANKAbout vid: https://youtu.be/kTuiDadgcso?feature=sharedWhat's more "INTERESTING" for me is the FUNDING. Notice:£100MILLION (£25MILLION each) from four pharmaceutical companies: Amgen ASTRAZENECA GlaxoSmithKline Johnson & Johnsonhttps://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/our-funding-NHS say:The NHS is exploring the 'introduction' of innovative genomic sequencing techniques that can be applied to a range of clinical applications, including CANCER. For example: LIQUID BIOPSIES Now... it gets 'really' interesting when they say... Over the next 1 3 YEARS the NHS "WILL" evolve the genomic testing strategy to develop an integrated diagnostic model and a multi-modal "MULTIOMICS" testing approach, utilising multiple DNA and RNA based technologies across existing care pathways, clinical conditions and disease areas. This will support preventative healthcare, earlier diagnosis and faster access to precision treatments. It will also explore whether other diagnostics associated with the functional genomics pathway should be introduced, for example "PROTEOMICS". https://www.england.nhs.uk/long-read/accelerating-genomic-medicine-in-the-nhs/In above link - also NOTE - the ref to LUNG cancer in the LB case studies - where TISSUE biopsy is not feasible. Coincidental AGLs latest news was for LUNG? https://www.londonstockexchange.com/news-article/AGL/analysis-of-ctc-dna-and-ctdna-using-illumina-assay/16873903-ASTRAZENECA:In "PROTEOMICS" and metabolomics, we use state-of-the-art mass spectrometry to identify and quantify "PROTEINS", metabolites and lipids and work out which changes occur "DURING" disease or "AFTER" TREATMENT. https://www.astrazeneca.com/r-d/our-technologies/multi-omics.htmlAlso coincidental???That back in NOV24 AGL released this RNS:" ... is pleased to announce the publication of research investigating the "DUAL" analysis of CTCs and circulating tumour DNA (ctDNA) in non-small cell "LUNG" cancer ... " Researchers used the PARSORTIX system to isolate and harvest CTCs from 30 patients with EGFR-mutated NSCLC ("LUNG") that were undergoing treatment with osimertinib (TAGRISSO: ASTRAZENECA). Osimertinib is an EGFR inhibitor with annual revenues of US$6.7BILLION, growing at 16% per annum. https://www.londonstockexchange.com/news-article/AGL/parsortix-enriched-ctc-ctdna-in-nsclc-patients/16757138-CtDNA:PARSORTIX uniquely captures intact CTCs, enabling "PROTEOMICS" analysis of LIVE tumor cells - this is something GUARDANT HEALTH, ROCHE or any other ctDNA-focused companies "CANNOT DO". https://www.roche.com/stories/liquid-biopsy-in-oncology-The key limitation of both ASTRAZENECA's mass spectrometry and ILLUMINA's NGS-based "PROTEOMICS" is that they analyse PROTEINS from BULK blood plasma or serum samples. This means they provide a "BROAD" picture but "LACK" tumor-specific, real-time data. PARSORTIX = isolation of intact CTCs for LIVE... TUMOUR SPECIFIC... and... DYNAMIC MONITORING! https://angleplc.com/laboratory-services/?_gl=1*4zs87m*_up*MQ..*_ga*OTM2OTIwMjk3LjE3MzgyNjg2NzA.*_ga_1SBQYXCVE6*MTczODI2ODY3MC4xLjEuMTczODI2ODcxOS4wLjAuMA..-CONCLUSION: AGL "ENABLES" a level of "PRECISION" that ILLUMINA and mass spectrometry alone "CANNOT" provide - making it a vital piece in the NHS's evolving cancer research and treatment strategy.Meaning: AGL has an "EXCLUSIVE LANE" in this emerging market and if ILLUMINA, ASTRAZENECA, or the NHS 'want' full MULTIOMIC insights - DNA + "PROTEIN" then...ANGLE . . .IS . . .THE . . ."ONLY" . . .VIABLE . . .SOLUTION!!!-AGL even promoting the "NHS NARRATIVE": https://www.healthawareness.co.uk/supporting-the-nhs/why-ctcs-and-liquid-biopsies-could-one-day-revolutionise-nhs-cancer-care/ANGLE could very well be "BRITAINS BIOTECH BULLDOG" - ready to shake up the status quo.-ATB |
i can tell you one deal
Illumina bought Grail for 7 billion,
Grail had absolutely zero earnings at the time.
Hope this helps your understanding of the current liquid biopsy space. |
Any valuations on these deals ?? Still if the share price goes up less dilution when the rights hits ! Well done anyone that got in early ! A gambling share this one |
It’s in a very profound gap fill on chart to near 30 pence !
For longs. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
